U.S. Securities and Exchange Commission
                             Washington, D.C. 20549

                                   Form 10-QSB

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES  EXCHANGE ACT OF 1934

For the quarter ended: June 30, 2001

Commission file no.:  000-31889

                               Bio-One Corporation
                  --------------------------------------------
                 (Name of small business issuer in its charter)

             Nevada                                              65-0815746
-------------------------------                            --------------------
(State or other jurisdiction of                            (I.R.S. Employer
incorporation or organization)                               Identification No.)

310 Waymont Court, Suite 100
Lake Mary, Florida                                           32746
----------------------------------------                   ---------------
(Address of principal executive offices)                     (Zip Code)

Issuer's telephone number (407) 328-1611

Securities registered under Section 12(b) of the Exchange Act:

                                                      Name of each exchange on
      Title of each class                             which registered

                None                                         None
-----------------------------                         -------------------------

Securities registered under Section 12(g) of the Exchange Act:

                         Common Stock, $0.001 par value
                       -----------------------------------
                                (Title of class)

Copies of Communications Sent to:
                                       Mintmire & Associates
                                       265 Sunrise Avenue, Suite 204
                                       Palm Beach, FL 33480
                                       Tel: (561) 832-5696
                                       Fax: (561) 659-5371


<PAGE>



     Indicate by Check  whether the issuer (1) filed all reports  required to be
filed by Section 13 or 15(d) of the  Exchange  Act during the past 12 months (or
for such shorter  period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days.

                  Yes  X        No
                      ---         ----

     As of June 30, 2001,  there were  10,632,999  shares of voting stock of the
registrant issued and outstanding.



<PAGE>



                                     PART I

Item 1.           Financial Statements



                               BIO-ONE CORPORATION

                                      Index

                                                                            Page
                                                                          Number

Item 1.           Financial Statements

Balance Sheets  June 30, 2001 (Unaudited) and December 31, 2000              F-3

Statements of Operations Three months and six months ended
June 30, 2001 (Unaudited) and June 30, 2000 (Unaudited)                      F-5

Statements of Cash Flows Six months ended June 30, 2001 (Unaudited)
and June 30, 2000 (Unaudited)                                                F-6

Notes to Financial Statements (Unaudited)                                    F-7








<PAGE>





<TABLE>
<CAPTION>
                                                    BIO-ONE CORPORATION

                                                       Balance Sheets


                                     Assets
                                                                December 31,      June 30, 2001
                                                                    2000           (Unaudited)
                                                             -----------------  ------------------
<S>                                                          <C>                <C>
Current assets:
     Cash and cash equivalents                               $         19,832              48,431
     Accounts receivable                                                1,930               3,402
     Inventories                                                       19,901              18,883
                                                             -----------------  ------------------

              Total current assets                                     41,663              70,716

 Property and equipment, at cost,
 net of accumulated depreciation and amortization                      14,906              23,919

     Deposits                                                           1,700               1,700
                                                             -----------------  ------------------

              Total assets                                   $         58,269              96,335
                                                             =================  ==================


                      Liabilities and Shareholders' Equity

Current liabilities:
     Accounts payable                                        $         30,160              20,141
     Accrued expenses                                                 203,468             251,468
     Current installments of note payable                             124,502             174,502
                                                             -----------------  ------------------

                Total current liabilities                             358,130             446,111
                                                             -----------------  ------------------


Shareholders' equity:
 Common stock - $.001 par value, authorized 100 million
        shares; issued 9,844,999 and 10,456,999 shares                  9,845              10,456
     Additional paid in capital                                       279,255             431,644
     Accumulated deficit                                             (588,961)           (791,876)
                                                             -----------------  ------------------

               Total shareholders' equity                            (299,861)           (349,776)
                                                             -----------------  ------------------

                                                             $         58,269              96,335
                                                             =================  ==================
</TABLE>



                 See accompanying notes to financial statements.

                                      F-3

<PAGE>




<TABLE>
<CAPTION>
                               BIO-ONE CORPORATION

                            Statements of Operations

                                                                     Three Months Ended                 Six Months Ended
                                                                June 30,                                    June 30,
                                                                  2000                2001             2000             2001
                                                              (Unaudited)         (Unaudited)      (Unaudited)      (Unaudited)
                                                            ----------------    -------------    -------------    -------------
<S>                                                         <C>                 <C>              <C>              <C>
Revenues:
     Net sales                                              $         19,712           23,077           19,712           35,867
     Consulting fees                                                       -                -           18,958                -
                                                            ----------------    -------------    -------------    -------------

                                                                      19,712           23,077           38,670           35,867

Costs and expenses:
     Cost of goods sold                                               14,187           13,573           14,187           20,457
     Selling, general and administrative                              99,440          112,163          141,400          212,496
                                                            ----------------    -------------    -------------    -------------

                                                                     113,627          125,736          155,587          232,953
                                                            ----------------    -------------    -------------    -------------

              Operating income (loss)                                (93,915)        (102,659)        (116,917)        (197,086)

Non-operating revenue (expense):
     Interest expense                                                    (93)          (2,060)             (93)          (5,829)
                                                            ----------------    -------------    -------------    -------------

              Income before income taxes                             (94,008)        (104,719)        (117,010)        (202,915)

Provision for income taxes                                                 -                -                -                -

              Net income                                    $        (94,008)        (104,719)        (117,010)        (202,915)
                                                            ================    =============    =============    =============

Basic earnings per share                                    $          (0.02)           (0.01)           (0.02)           (0.02)
                                                            ================    =============    =============    =============

Diluted earnings per share                                  $          (0.02)           (0.01)           (0.02)           (0.02)
                                                            ================    =============    =============    =============

Weighted average number of shares outstanding                      4,994,500       10,369,499        4,994,500       10,244,499
                                                            ================    =============    =============    =============
</TABLE>


                 See accompanying notes to financial statements.

                                      F-4



<PAGE>




<TABLE>
<CAPTION>
                               BIO-ONE CORPORATION

                            Statements of Cash Flows

                                                                              Six Months Ended
                                                                                   June 30,
                                                                               2000                2001
                                                                        (Unaudited)         (Unaudited)
                                                                     --------------     ---------------
<S>                                                                  <C>                <C>
Cash flows from operating activities:
    Net loss                                                         $     (117,010)           (202,915)
    Adjustments to reconcile net income to net cash
        provide by operating activities:
           Depreciation and amortization                                      1,200               2,000
           Common stock issued for services                                       -               3,000
           Changes in operating assets and liabilities:
              Accounts receivable                                            (1,939)             (1,472)
              Inventories                                                     2,600               1,018
              Accounts payable and accrued expenses                          48,623              37,981
              Other assets                                                   (7,000)                  -
                                                                     --------------     ---------------

                   Net cash used in operating activities                    (73,526)           (160,388)
                                                                     --------------     ---------------

Cash flows from investing activities:
    Purchase of property and equipment
                                                                               (730)            (11,013)
                                                                     --------------     ---------------

                   Net cash used in investing activities                       (730)            (11,013)
                                                                     --------------     ---------------

Cash flows from financing activities:
    Proceeds from sale of common stock                                       67,100             150,000
    Payment of principal on note payable                                          -             (25,000)
    Proceeds from note payable                                                4,500              75,000
                                                                     --------------     ---------------

                   Net cash provided by financing activities                 71,600             200,000
                                                                     --------------     ---------------

                   Increase in cash and cash equivalents                     (2,656)             28,599

Cash and cash equivalents - beginning of period                                  20              19,832
                                                                     --------------     ---------------

Cash and cash equivalents - end of period                            $       (2,636)             48,431
                                                                     ==============     ===============
</TABLE>


                 See accompanying notes to financial statements.

                                      F-5


<PAGE>


                               BIO-ONE CORPORATION

                          Notes to Financial Statements



(1)  Presentation of Unaudited Financial Statements

The unaudited  financial  statements have been prepared in accordance with rules
of the Securities and Exchange  Commission  and,  therefore,  do not include all
information  and  footnotes  necessary  for a  fair  presentation  of  financial
position,  results of operations  and cash flows,  in conformity  with generally
accepted accounting  principles.  The information  furnished,  in the opinion of
management,  reflects  all  adjustments  (consisting  only of  normal  recurring
accruals)  necessary  to present  fairly the  financial  position as of June 30,
2001, and results of operations  and cash flows for the six-month  periods ended
June 30, 2001 and 2000. The results of operations are not necessarily indicative
of results which may be expected for any other interim  period,  or for the year
as a whole.

(2)  Sales to Major Customers

During the six months ended June 30, 2001,  three  customers  accounted for 51%,
19% and 17%, respectively, of total revenue.

(3)  Inventories

Inventories consist of the following:


                           December 31,        June 30, 2001
                            2000                (Unaudited)
                           -------------       -------------

Finished goods                 $  19,901              18,883
                           =============       =============



                                      F-6



<PAGE>




Item 2. Management's Discussion and Analysis of Results of Operations.

General

     Bio-One Corporation, a Nevada corporation of which Crown Enterprises, Inc.,
a Florida corporation ("Crown") is a wholly-owned  subsidiary  (collectively the
"Company")  relied upon Section 4(2) of the  Securities  Act of 1933, as amended
(the "Act") and Rule 506 of Regulation D promulgated thereunder ("Rule 506") for
several transactions regarding the issuance of its unregistered  securities.  In
each  instance,  such  reliance was based upon the fact that (i) the issuance of
the  shares  did not  involve a public  offering,  (ii)  there were no more than
thirty-five  (35)  investors  (excluding  "accredited  investors"),  (iii)  each
investor who was not an accredited  investor  either alone or with his purchaser
representative(s)  has such  knowledge and  experience in financial and business
matters that he is capable of evaluating the merits and risks of the prospective
investment,  or the issuer reasonably  believes  immediately prior to making any
sale that such  purchaser  comes  within this  description,  (iv) the offers and
sales were made in compliance  with Rules 501 and 502, (v) the  securities  were
subject to Rule 144  limitations  on resale and (vi) each of the  parties  was a
sophisticated  purchaser and had full access to the  information  on the Company
necessary to make an informed investment decision by virtue of the due diligence
conducted  by  the  purchaser  or  available  to  the  purchaser  prior  to  the
transaction (the "506 Exemption").

     The Company relied upon Section 517.061(11) of the Florida Code for several
transactions.  In each case, the facts relied upon to make the Florida Exemption
applicable  include the following:  (i) sales of the shares of common stock were
not made to more than 35 persons;  (ii) neither the offer nor the sale of any of
the shares was accomplished by the publication of any  advertisement;  (iii) all
purchasers either had a preexisting  personal or business  relationship with one
or more of the executive officers of the Company or, by reason of their business
or financial  experience,  could be  reasonably  assumed to have the capacity to
protect  their own  interests  in  connection  with the  transaction;  (iv) each
purchaser  represented that he was purchasing for his own account and not with a
view to or for sale in connection with any  distribution of the shares;  and (v)
prior to sale,  each  purchaser  had  reasonable  access to or was furnished all
material books and records of the Company,  all material contracts and documents
relating to the proposed  transaction,  and had an  opportunity  to question the
executive  officers of the Company.  Pursuant to Rule  3E-500.005,  in offerings
made under Section  517.061(11) of the Florida Statutes,  an offering memorandum
is not required; however each purchaser (or his representative) must be provided
with or  given  reasonable  access  to full  and  fair  disclosure  of  material
information.  An  issuer  is deemed to be  satisfied  if such  purchaser  or his
representative  has been given access to all  material  books and records of the
issuer;   all  material   contracts  and  documents  relating  to  the  proposed
transaction;  and an opportunity to question the appropriate  executive officer.
In the regard,  the Company supplied such information and was available for such
questioning (the "Florida Exemption").

     In January 2001, the Company entered into a consulting agreement with Irwin
Newman to provide  capital  raising,  revenue  building  and counsel  management
services.  In July 2001,  the Company issued 285,624 shares and 31,735 shares of
its restricted common stock to Mr. Newman and Mr. Jeffrey Gerstein respectively,
in compliance  with this agreement.  For such offering,  the Company relied upon
the 506 Exemption and the Florida Exemption.



<PAGE>



     In May 2001,  the Company  issued  100,000 shares of its common stock and a
warrant to  purchase  an  additional  100,000  shares of its common  stock at an
exercise price of $0.29 to Arthur  Szatkowski for $25,000.  The warrants  expire
June 22, 2002. For such offering,  the Company relied upon the 506 Exemption and
the Florida Exemption.

     In June 2001,  the Company issued 10,000 shares of its common stock to Curt
Jones, who served as a financial  consultant to the Company.  For such offering,
the Company relied upon the 506 Exemption and the Florida Exemption.

     In June 2001,  the  Company  issued  2,000  shares of its  common  stock to
Charles A.  Gaudio & MaryAnn  Gaudio  JTWROS for  services  in  connection  with
production of the Company's website. For such offering,  the Company relied upon
the 506 Exemption and the Florida Exemption.

     In July 2001,  the Company  filed a  Registration  Statement on Form S-8 to
register its Year 2001 Employee/Consultant  Stock Compensation Plan. The Company
registered 250,000 shares of its common stock, all of which was issued to Donald
F. Mintmire for legal fees.

     In July 2001, the Company announced the formation of its management team in
a press release dated July 17, 2001. The release may have been misleading,  as a
portion  of the  management  team has been  selected  by the  Company's  current
officers and directors, but as of yet has not been installed.

Discussion and Analysis

     The following  discussion and analysis  should be read in conjunction  with
the financial  statements of the Company and the  accompanying  notes  appearing
subsequently under the caption "Financial  Statements." The following discussion
and  analysis  contains  forward-looking  statements,  which  involve  risks and
uncertainties in the  forward-looking  statements.  The Company's actual results
may differ  significantly from the results,  expectations and plans discussed in
the forward- looking statements.

     The Company's  growth is expected to come  primarily from the private label
manufacture and wholesale  distribution  of human and animal health  supplements
and supply of ingredients (nutraceutical based health supplements) for inclusion
in  health  supplements.  This  pattern  of growth  will  closely  correlate  to
increases in the Company's  health  supplement  manufacturing  and  distribution
capacity and its development of proprietary health supplement technologies.

     On May 30,  2000,  the  Company  acquired  Crown.  By  acquiring  Crown,  a
"cottage" private label distributor of health supplements,  the Company acquired
technology and a proprietary nutritional supplements product line. The operation
produced  only  nominal   revenues  in  1999.   Operations   for  private  label
manufacturing  and  distribution  are expected to begin after  raising the funds
necessary  to purchase an existing  manufacturing  facility  and a  distribution
company.  Company  management  estimates  that $20  million  will be  needed  to
purchase  such both  facilities.  The monies needed are expected to be raised by
the Company through private placement efforts through the investment  community.
The Company is  currently in  negotiations  with  funding  sources,  although no
commitments  have been  made.  The  Company  has also  begun  talks with two (2)
possible acquisition candidates, although no binding agreement has been made.



<PAGE>



     In addition to private label distribution, the Company also benefitted from
its development of its Live Blood Cell Analysis  program the second half of 1999
and first half of 2000.  The  Company  conducted  extensive  experimentation  to
develop the trademarked  GREEN  PEARLS(TM)  product line and the process for the
capsuling of BLUE GREEN ALGAE FROM UPPER LAKE KLAMATH with extended  shelf-life.
GREEN  PEARLS(TM) is a unique  natural food source,  which is a standard  health
food supplement for maintaining  individual health. By mid-1999, the Company had
perfected  a  process  for  producing  GREEN  PEARLS(TM)  with  a two  (2)  year
shelf-life.  The  Company  began  distribution  of GREEN  PEARLS(TM)  to several
customers in the second quarter of 1999.

     Since acquiring  Crown,  the Company has begun to make  preparations  for a
period of growth,  which may require it to  significantly  increase the scale of
its operations. This increase will include the hiring of additional personnel in
all functional areas and will result in significantly higher operating expenses.
The  increase in  operating  expenses is expected to be matched by a  concurrent
increase in revenues.  However,  the  Company's  net loss may  continue  even if
revenues  increase  and  operating  expenses  may still  continue  to  increase.
Expansion of the  Company's  operations  may cause a  significant  strain on the
Company's  management,  financial and other resources.  The Company's ability to
manage recent and any possible future growth,  should it occur, will depend upon
a significant  expansion of its accounting and other internal management systems
and the  implementation  and  subsequent  improvement  of a variety of  systems,
procedures and controls.  There can be no assurance that significant problems in
these areas will not occur.  Any failure to expand these areas and implement and
improve such systems,  procedures and controls in an efficient  manner at a pace
consistent with the Company's  business could have a material  adverse effect on
the Company's  business,  financial  condition and results of  operations.  As a
result of such expected expansion and the anticipated  increase in its operating
expenses,  as well as the difficulty in forecasting  revenue levels, the Company
expects to continue to  experience  significant  fluctuations  in its  revenues,
costs and gross margins, and therefore its results of operations.

Results of  Operations  -For the Three Months  Ending June 30, 2001 and June 30,
2000

Financial Condition, Capital Resources and Liquidity

     For the 2nd  quarter  ended June 30,  2001 and June 30,  2000,  the Company
recorded revenues of $23,077 and $19,712 respectively.

     For the 2nd quarter ended June 30, 2001 and June 30, 2000,  the Company had
selling,  general and  administrative  expenses and total operating  expenses of
$112,163  and  $99,440  respectively.  This  increase  of  $12,723  was  due  to
employment  contract fees accrued for the Company's  management as well as legal
and accounting expenses.

     For the 2nd  quarter  ended June 30,  2001 and June 30,  2000,  the cost of
goods sold was $13,573 and $14,187 respectively.

Net Losses

     For the 2nd quarter ended June 30, 2001 the Company  reported a net loss of
$104,719.  For the 2nd quarter  ended June 30,  2000 the Company  reported a net
loss of $94,008. The increased loss


<PAGE>



is  primarily  due  to  employment  contract  fees  accrued  for  the  Company's
management as well as legal and accounting expenses.

     The ability of the Company to continue as a going concern is dependent upon
increasing sales and obtaining additional capital and financing.  The Company is
currently seeking  financing to allow it to continue its planned  operations and
is presently negotiating investment terms and conditions.

Employees

     At June 30, 2001,  the Company  employed two (2) persons.  Neither of these
employees  are   represented  by  a  labor  union  for  purposes  of  collective
bargaining.  The  Company  considers  its  relations  with its  employees  to be
excellent.  The  Company  plans to employ  additional  personnel  as needed upon
product rollout to accommodate fulfillment needs.

Research and Development

     Health Supplement  Development:  The Company develops products requested by
customers,  and/or develops new product concepts which it licenses to customers.
The Company also  actively  seeks and reviews new  nutraceutical  materials  and
delivery  technologies  developed  by  independent  researchers.   There  is  no
assurance  that this research and  development  effort will result in marketable
products or services.

Forward-Looking Statements

     This Form 10-QSB includes  "forward-looking  statements" within the meaning
of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the
Securities  Exchange  Act of  1934,  as  amended.  All  statements,  other  than
statements of historical  facts,  included or  incorporated by reference in this
Form 10-QSB which address  activities,  events or developments which the Company
expects or anticipates will or may occur in the future, including such things as
future capital expenditures (including the amount and nature thereof), expansion
and growth of the Company's business and operations,  and other such matters are
forward-looking  statements.  These statements are based on certain  assumptions
and analyses made by the Company in light of its  experience  and its perception
of historical  trends,  current  conditions and expected future  developments as
well as other factors it believes are appropriate in the circumstances. However,
whether  actual  results  or  developments   will  conform  with  the  Company's
expectations and predictions is subject to a number of risks and  uncertainties,
general economic market and business conditions;  the business opportunities (or
lack  thereof)  that may be presented to and pursued by the Company;  changes in
laws or regulation;  and other factors,  most of which are beyond the control of
the Company.

     Consequently,  all of the  forward-looking  statements  made in  this  Form
10-QSB  are  qualified  by  these  cautionary  statements  and  there  can be no
assurance  that the actual  results or  developments  anticipated by the Company
will be realized  or, even if  substantially  realized,  that they will have the
expected consequence to or effects on the Company or its business or operations.





<PAGE>



PART II

Item 1.  Legal Proceedings.

     The  Company  knows  of no legal  proceedings  to which it is a party or to
which any of its  property  is the  subject  which are  pending,  threatened  or
contemplated or any unsatisfied judgments against the Company.

Item 2. Changes in Securities and Use of Proceeds

         None.

Item 3. Defaults in Senior Securities

         None

Item 4. Submission of Matters to a Vote of Security Holders.

     No matter was submitted during the quarter ending June 30, 2001, covered by
this report to a vote of the Company's shareholders, through the solicitation of
proxies or otherwise.

Item 5. Other Information

         None.

Item 6. Exhibits and Reports on Form 8-K

     (a) The exhibits  required to be filed  herewith by Item 601 of  Regulation
S-B, as described in the following index of exhibits, are incorporated herein by
reference, as follows:

Item 1.           Index to Exhibits

<TABLE>
<S>      <C>      <C>
3.(i).1  [1]      Articles of Incorporation of Bio-One Corporation filed February 24, 1998.

3.(i).2  [1]      Certificate of Amendment of Articles of Incorporation increasing authorized capital
                  stock filed August 7, 2000.

3.(ii).1 [1]      Bylaws of Bio-One Corporation

4.1      [1]      Form of Private Placement Offering of 1,600,000 common shares at $0.01 per share.

4.2      [1]      Promissory Note in favor of Kevin Thomas dated August 8, 2000.

4.3      [2]      Convertible Note in favor of Margaret Schrock dated December 5, 2000.

5.1      [3]      Opinion of Mintmire & Associates.

10.1     [1]      Share Exchange Agreement between the Company and Crown Enterprises, Inc. dated
                  May 20, 2000.
</TABLE>



<PAGE>


<TABLE>
<S>      <C>      <C>
10.2     [1]      Employment Agreement between the Company and Armand Dauplaise dated May
                  30, 2000.

10.3     [1]      Employment Agreement between the Company and Kevin Lockhart dated May 30,
                  2000.

10.4     [1]      Lease Agreement between Crown Enterprises and Daniel Jack Co. dated August 15,
                  2000.

10.5     [2]      Removed.

10.6     [3]      Bio-One Corporation Year 2001  Employee/Consultant Stock Compensation Plan.

10.7      *       Consulting Agreement between the Company and Irwin Newman dated January 17,
                  2001.

23.1     [3]      Consent of Parks, Tschopp, Whitcomb  & Orr, P.A.

23.2     [3]      Consent of Mintmire & Associates  (contained in the opinion filed as Exhibit 5.3).
-------------------------------------------------
</TABLE>

[1]  Incorporated herein by reference to the Company's Registration Statement on
     Form 10-SB filed November 3, 2000.
[2]  Incorporated  herein by reference  to the  Company's  amended  Registration
     Statement on Form 10-SB filed January 5, 2001.
[3]  Incorporated herein by reference to the Company's Registration Statement on
     Form S-8 filed July 20, 2001.

     (b) No reports on Form 8-K have been filed.

Item 2.  Description of Exhibits

     The documents  required to be filed as Exhibits  Number 2 and 6 and in Part
III of Form 1-A filed as part of this  Registration  Statement on Form 10-SB are
listed in Item 1 of this Part III above.  No documents  are required to be filed
as Exhibit  Numbers 3 , 5 or 7 in Part III of Form 1-A and the reference to such
Exhibit  Numbers is therefore  omitted.  The following  additional  exhibits are
filed hereto:












<PAGE>








                                   SIGNATURES
                          -----------------------------

         In accordance with the requirements of the Exchange Act, the registrant
caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.

                               Bio-One Corporation
                    ----------------------------------------
                                  (Registrant)


Date: August 10, 2001      By: /s/ Armand Dauplaise
                           -----------------------------------
                           Armand Dauplaise, President and Chairman


                           By: /s/ Kevin Lockhart
                           ------------------------------------
                           Kevin Lockhart, Secretary